A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma

Trial Profile

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Avadomide (Primary) ; Obinutuzumab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 25 Jun 2017 Results (n=34, Data cut off 12 January 2017), presented at the 22nd Congress of the European Haematology Association
    • 09 May 2017 Planned number of patients changed from 48 to 79.
    • 09 May 2017 Planned End Date changed from 5 Oct 2017 to 16 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top